The FDA warns that both CJC-1295 and ipamorelin carry risks of immunogenicity (triggering immune responses) and cardiovascular effects, including "increased heart rate and systemic vasodilatory reaction." One clinical trial of CJC-1295 was discontinued following a participants death, though the attending physician believed the event was "unrelated to treatment." Neither CJC-1295 nor ipamorelin is FDA-approved
LY4101174, which carries an exatecan payload, is currently undergoing a phase I trial in patients with advanced/metastatic solid tumors, including prostate cancer (NCT06238479) 186
In addition to its antioxidant action, glutathione is also involved in the intracellular neutralization of toxins
Known for its profound regenerative potential, BPC-157 supports tissue healing far beyond the gutbenefiting tendons, ligaments, vasculature, the nervous system, and more